RELENT research aims not only at developing new research tools and technologies but also validating and implementing methods to measure disease activity and monitor treatment more accurately thus avoiding drug toxicity and side effects such as infections. Three SME partners (EMC, Hycult, EMC), or immunological tests by partner 11 (Hycult) and a biorepository of iPSC lines from patients with the autoimmune diseases we investigate by partner 12.
Delivering these resources to the scientific community of European and global markets will strengthen the strategic position and competitiveness of the RELENT SME partners and contribute to their growth.